Pfizer Inc (NYSE: PFE) has reported E.P.S. of $0.79 for its third fiscal quarter (ending September 30) versus $-0.42 for the same period a year ago — a decline of -288%. E.P.S. were $0.76 for the latest four quarters through September 30 versus $1.86 for the same period a year ago — a decline of -59%.
Recent Price Action
Pfizer Inc (NYSE: PFE) stock declined modestly by -1.4% on 10/29/24. The stock closed at $28.46. Moreover, exceptionally high trading volume at 341% of normal accompanied the decline. The stock has been strong relative to the market over the last nine months but has declined -1.6% during the last week.
Current PriceTarget Research Rating
PFE is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Pfizer has a current Value Trend Rating of B (Positive). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Pfizer has a slightly positive Power Rating of 62 and a good Appreciation Score of 77, producing the Positive Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment